Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonoma Pharmaceuticals Inc (NQ: SNOA )

2.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonoma Pharmaceuticals Inc

< Previous 1 2 Next >
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
Via ACCESSWIRE
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
Via ACCESSWIRE
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
Via ACCESSWIRE
Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant
Via ACCESSWIRE
These Four Companies Are Attracting Investors Following Recent News
Via AB Newswire
Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
Via ACCESSWIRE
Sonoma Pharmaceuticals (NASDAQ: SNOA) and EMC Pharma Receives DAPA Registration for Microcyn Rx Products from U.S. Department of Defense
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a global healthcare company that is focused on the research, development and production of 
Via Spotlight Growth
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
Via ACCESSWIRE
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results
WOODSTOCK, GA / ACCESSWIRE / July 13, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous... 
From Sonoma Pharmaceuticals, Inc.
Via AccessWire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.